Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Renal Assessment Clear all
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

NCT02607553
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 26, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

NCT03324373
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy
Drug · Procedure
Lead sponsor
Yousef Zakharia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 26, 2026, 10:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

APOL1 Genetic Testing in African Americans

NCT05656261
View directory record Official record
Conditions
Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities
Interventions
Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
Genetic
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

NCT04549597
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 90 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 26, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
rapcabtagene autoleucel, rituximab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542
View directory record Official record
Conditions
Renal Impairment
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Jacksonville, Florida • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

NCT01238796
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 26, 2026, 10:03 AM EDT
Completed No phase listed Observational

Ferumoxytol Enhanced Hyperfine Low Field Strength MRI

NCT04721262
View directory record Official record
Conditions
Anemia, Hemolytic
Interventions
Hyperfine Portable MRI
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

NCT00685061
View directory record Official record
Conditions
Renal Transplantation
Interventions
Thymoglobulin, Campath-1H, Daclizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

NCT02762006
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Moshe Ornstein
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

NCT00616811
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, Sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

NCT01780844
View directory record Official record
Conditions
Kidney Transplantation
Interventions
ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF), Basiliximab, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus

NCT03760263
View directory record Official record
Conditions
Transplant;Failure,Kidney
Interventions
Tacrolimus
Drug
Lead sponsor
Sentara Norfolk General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

NCT05760300
View directory record Official record
Conditions
Chronic Hepatitis D Infection
Interventions
Bulevirtide (BLV)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Edgewater, Florida • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 26, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

NCT00022633
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 26, 2026, 10:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

NCT03372109
View directory record Official record
Conditions
Body Weight Changes
Interventions
Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 26, 2026, 10:03 AM EDT